Four different Phase I studies, on a total of 92 humans, were conducted.
SCO-101 was found to be non-toxic.
The clinical Phase II trial with metastatic colorectal cancer patients consist of two parts. The first part will include 12-18 patients and have safety and toxicity as primary endpoints. The first part will identify the most optimal dose of SCO-101 in combination with chemotherapy. The second part will include 15-25 patients and have efficacy as the primary endpoint.